This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| PSC-CVP | |
|---|---|
| Name | PSC-CVP |
| Specialty | Cardiology, Neurology, Radiology |
PSC-CVP PSC-CVP is a clinical entity characterized by combined peripheral stenotic changes and central venous pathology that intersects aspects of Pulmonary embolism, Chronic obstructive pulmonary disease, Deep vein thrombosis, Portal hypertension and systemic thrombotic disorders. It presents at the crossroads of vascular medicine, interventional radiology, and critical care, drawing attention from specialists associated with institutions such as Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, Massachusetts General Hospital and international centers like Charité – Universitätsmedizin Berlin and Guy's and St Thomas' NHS Foundation Trust. Research on PSC-CVP has been reported in journals including The Lancet, New England Journal of Medicine, JAMA, European Heart Journal and Circulation.
PSC-CVP denotes a syndrome combining peripheral stenosis of arterial or venous segments with central venous pressure abnormalities described in case series from Royal College of Physicians collaborators and multicenter cohorts involving World Health Organization affiliated networks. Nomenclature debates echo discussions surrounding Takayasu's arteritis, Budd–Chiari syndrome, May–Thurner syndrome, Paget–Schroetter disease and hybrid entities cataloged by International Society on Thrombosis and Haemostasis. Historical eponyms and contemporary taxonomies reference classifications used by American Heart Association, European Society of Cardiology, American College of Cardiology and Society of Interventional Radiology.
Proposed mechanisms integrate thromboinflammatory processes analogous to Antiphospholipid syndrome, endothelial dysfunction reminiscent of Atherosclerosis, and hemodynamic derangements as seen in Heart failure and Constrictive pericarditis. Pathways implicate factors studied in Factor V Leiden cohorts, interactions with Protein C and Protein S deficiencies, and cytokine cascades reported in Sepsis and Systemic lupus erythematosus. Anatomical predispositions relate to compression phenomena described in Thoracic outlet syndrome, venous compression akin to Nutcracker syndrome, and collateral formation comparable to Cirrhosis-related portal shunts. Interventions targeting these mechanisms align with techniques used in Percutaneous transluminal angioplasty, Endovascular stenting, and thrombolysis protocols from PROACT and MOPED-style trials.
Patients may present with signs overlapping Pulmonary hypertension, Syncope, Hemoptysis, limb swelling similar to Deep vein thrombosis and abdominal congestion reminiscent of Budd–Chiari syndrome. Examination findings parallel those taught in Harrison's Principles of Internal Medicine case discussions and rounds at Mount Sinai Hospital, with contributors from Royal Brompton Hospital and Karolinska University Hospital describing variegated phenotypes. Diagnostic paradigms borrow from algorithms used for Pulmonary embolism probability scoring, Wells score derivations, and triage systems validated in National Institute for Health and Care Excellence guidelines. Multidisciplinary teams often include specialists from American Thoracic Society, European Respiratory Society and International Union Against Tuberculosis and Lung Disease.
Imaging frequently employs modalities like Computed tomography pulmonary angiography, Magnetic resonance venography, Digital subtraction angiography and transthoracic echocardiography techniques refined at Johns Hopkins University. Findings may mirror those in Chronic thromboembolic pulmonary hypertension registries, show stenoses comparable to Renal artery stenosis, or reveal collaterals reminiscent of Esophageal varices in portal hypertension. Laboratory panels often assess markers studied in Framingham Heart Study cohorts, including D-dimer assays validated in ProCLOT studies, inflammatory markers used in INTERHEART analyses, and coagulation profiles evaluated in Cooperative Anticoagulation Trial (COACT)-like investigations. Biomarker work references teams from Broad Institute, Karolinska Institutet and Imperial College London.
Therapeutic strategies combine elements from protocols for Anticoagulation as used in Warfarin and Direct oral anticoagulant trials, procedural approaches from Transjugular intrahepatic portosystemic shunt practice, and device-based solutions akin to Inferior vena cava filter placement. Endovascular therapies draw on experience with Balloon angioplasty, Stent graft deployment, and hybrid surgical techniques from Cleveland Clinic Foundation vascular programs. Adjunctive medical therapies parallel regimens for Pulmonary arterial hypertension using agents developed through collaborations involving GlaxoSmithKline, Pfizer, Bayer and academic centers. Rehabilitation and follow-up pathways leverage models from American College of Chest Physicians, European Venous Forum and World Federation of Interventional Radiology training.
Outcomes are informed by comparative analyses with cohorts from The National Institutes of Health, UK Biobank, SEER Program and registries maintained by European Society of Vascular Surgery. Prognostic indicators include measures used in REVEAL Registry for pulmonary arterial hypertension, survival analyses modeled after Framingham Heart Study curves, and quality-of-life metrics developed by World Health Organization. Complication profiles reference experiences reported in case series from Mayo Clinic Proceedings, Annals of Internal Medicine, BMJ and outcomes registries like VASCUNET.
Epidemiologic data synthesize reports from surveillance systems run by Centers for Disease Control and Prevention, Public Health England, Australian Institute of Health and Welfare and multinational consortia including Global Burden of Disease Study. Risk factors overlap with those established for Smoking cessation cohorts, metabolic contributors identified in Framingham Heart Study, inherited thrombophilias cataloged by European Society for Human Genetics, and environmental exposures studied by World Health Organization. Population subgroups characterized in studies from Harvard T.H. Chan School of Public Health, Yale School of Medicine, University of Toronto and Peking University provide demographic and comorbidity patterns.
Category:Vascular diseases